Why the study?
Although treatments for pulmonary arterial hypertension have improved over the last two decades, outcomes remain fatal, highlighting the need for newer drug targets beyond the three well-established pathways.
This review highlights the need for meticulous research and clinical trials to develop newer drugs targeting novel pathways in pulmonary arterial hypertension.
May inform selection of novel PAH targets; leaves open whether they will improve outcomes in trials.
Pulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.
No takes yet. Share an insight, caveat, or question.
Tyagi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: